A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Biogen
- Study ID
- NCT04442503
- Phase
- PHASE3
- Status
- Completed
Conditions
- Depression, Postpartum
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 45 Years
- Healthy Volunteers
- Not accepted
Interventions
- SAGE-217 — DRUGSAGE-217 oral capsules.
- Placebo — DRUGSAGE-217 matched-placebo oral capsules.
Study Details
The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.
Key Dates
- Start date
- Jun 8, 2020
- Status verified
- Nov 2023
- Primary completion
- Mar 15, 2022
- Completion
- Apr 12, 2022
Study Design
- Enrollment
- 200 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: PlaceboParticipants received SAGE-217 matched-placebo capsules, orally, once daily for 14 days.
- Experimental: SAGE-217 50 mgParticipants received SAGE-217, 50 mg, capsules, orally, once daily for 14 days.
Primary Outcome Measure
Change From Baseline (CFB) in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 [ Time Frame: Baseline and Day 15 ]
Locations (68)
Find similar trials in Scottsdale, AZ
Related Studies
- HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac DiagnosisRecruiting · Children's Hospital Medical Center, Cincinnati · Los Angeles, California
- Healing at Home 2.0 - Enhanced Chat Tool for Lowering Postpartum DepressionRecruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their PregnancyRecruiting · Biogen · Woonsocket, Rhode Island